Expert Video - What are the latest advances in treatment failure and relapse in AML?

Acute myeloid leukemia (AML) expert Dr. Jamile Shammo discusses recent advances in the  understanding of AML disease biology, which is changing the outcomes for patients. The importance of improved outcomes with combination-agent, and triple-agent therapy is becoming a new therapeutic area of importance in treating AML patients. Personalized patient care is becoming increasingly important in the future management of AML patients. The classical approach to AML treatment is induction, consolidation, and maintenance therapy. The relapsed patient is an area of focus in the future. Mutations are drivers of AML disease. Experts provide their own updates, based on their own clinical experience.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.